The report highlights early metabolic studies, selected clinical trials, and certain double-blind placebo-controlled investigations that examined markers such as: blood sugar regulation insulin sensitivity cholesterol levels impaired glucose tolerance adipose tissue activity fat release and lipolytic activity While these studies generated interest in AOD-9604 as a potential anti-obesity drug candidate , the report stresses that no authority recognizes it as an active treatment for obesity, weight loss, or human use and emphasizes that it remains designated strictly for research use
In genetically obese Zucker rats and ob/ob mice, AOD-9604 reduced body weight without affecting glycemic control, unlike growth hormone
Glucagon receptor agonism increases energy expenditure and promotes hepatic fatty acid oxidation, which may contribute to reductions in liver fat content
The relative abundance of the [ Eubacterium ] coprostanoligenes group was greater in both the vehicle- and 5A-1MQ-treated groups switched from WD to LD compared to the LD control group (Supplementary Fig
No prescription is required
Energy and metabolism support Physician-prescribed B12 (methylcobalamin) injections to support energy levels, metabolism, nerve function, and overall vitality
